CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 99 filers reported holding CUE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is 9.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $138 | -75.6% | 59,800 | -61.4% | 0.00% | -100.0% |
| Q2 2023 | $566 | +211.0% | 155,000 | +203.3% | 0.00% | – |
| Q1 2023 | $182 | -55.0% | 51,100 | -63.9% | 0.00% | -100.0% |
| Q4 2022 | $404 | -100.0% | 141,700 | -66.7% | 0.00% | 0.0% |
| Q3 2022 | $950,000 | -34.2% | 426,147 | -26.5% | 0.00% | -50.0% |
| Q2 2022 | $1,443,000 | -43.1% | 579,700 | +11.6% | 0.00% | -33.3% |
| Q1 2022 | $2,534,000 | +114.2% | 519,300 | +396.5% | 0.00% | +200.0% |
| Q4 2021 | $1,183,000 | +38.5% | 104,600 | +53.1% | 0.00% | 0.0% |
| Q4 2020 | $854,000 | -54.1% | 68,300 | -44.7% | 0.00% | -50.0% |
| Q3 2020 | $1,859,000 | -24.9% | 123,496 | +22.3% | 0.00% | 0.0% |
| Q2 2020 | $2,476,000 | +117.0% | 101,000 | +25.6% | 0.00% | +100.0% |
| Q1 2020 | $1,141,000 | +65.6% | 80,393 | +85.3% | 0.00% | 0.0% |
| Q4 2019 | $689,000 | – | 43,393 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 1,915,219 | $23,959,000 | 5.70% |
| Prosight Management, LP | 906,569 | $11,341,000 | 5.24% |
| P.A.W. CAPITAL CORP | 140,000 | $1,751,000 | 1.54% |
| Voss Capital, LLC | 220,714 | $2,761,000 | 1.39% |
| Robertson Stephens Wealth Management, LLC | 484,000 | $6,054,000 | 1.26% |
| Slate Path Capital LP | 1,483,619 | $18,560,000 | 1.00% |
| Nantahala Capital Management | 2,506,772 | $31,360,000 | 0.97% |
| PRECEPT MANAGEMENT LLC | 150,000 | $1,877,000 | 0.76% |
| SANDERS MORRIS HARRIS LLC | 193,591 | $2,449,000 | 0.56% |
| Rock Creek Group, LP | 100,014 | $1,251,000 | 0.51% |